Oxford BioMedica Announces Ocular Programme Update

Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that the first dose level of RetinoStat(R) is safe and well-tolerated at one month following treatment...

Full Story →